Symmetry Medical Goes Negative
Symmetry Medical (NYS: SMA) filed its 10-K on Thursday. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Symmetry Medical beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank, and GAAP earnings per share shrank to a loss.
Margins shrank across the board.
Symmetry Medical logged revenue of $84.5 million. The two analysts polled by S&P Capital IQ predicted net sales of $80 million on the same basis. GAAP reported sales were 12% lower than the prior-year quarter's $96 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.01. The four earnings estimates compiled by S&P Capital IQ forecast $0.04 per share on the same basis. GAAP EPS were -$0.09 for Q4 versus $0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.1%, 630 basis points worse than the prior-year quarter. Operating margin was 4.9%, 450 basis points worse than the prior-year quarter. Net margin was -3.8%, 830 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $99.3 million. On the bottom line, the average EPS estimate is $0.09.
Next year's average estimate for revenue is $418.1 million. The average EPS estimate is $0.56.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Symmetry Medical is outperform, with an average price target of $11.25.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Symmetry Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Symmetry Medical to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.